ADMA Biologics (ADMA) Receives FDA Label Expansion for ASCEN…

ADMA Biologics Inc. (NASDAQ:ADMA) is one of the best cheap stocks under $10 to buy in June. On May 4, ADMA Biologics received FDA approval to expand the label for its specialty biologic, ASCENIV, to include pediatric patients aged two years and older. Previously, the treatment was restricted to primary humoral immunodeficiency/PI patients aged 12 and older. This approval follows the completion of a required post-marketing pediatric assessment and marks a significant expansion of the therapy’s reach.

CEO Adam Grossman stated that the expanded indication allows the company to address the needs of younger immune-compromised patients much earlier in their treatment journey. The clinical milestone highlights the success of the company’s pediatric assessment program, which was driven by collaborative efforts between ADMA’s operational teams, medical professionals, and participating families.

15 States with the Best Healthcare in the US

ASCENIV is a plasma-derived, polyclonal intravenous immune globulin manufactured using ADMA Biologics Inc.’s (NASDAQ:ADMA) proprietary donor screening and plasma pooling methodology. Protected by a portfolio of international patents, the product is designed to provide polyclonal antibodies that help the immune system neutralize bacteria and viruses. The company plans to prioritize the continued utilization of this treatment as a key option for pediatric care.

ADMA Biologics Inc. (NASDAQ:ADMA) is a biopharmaceutical company that manufactures, markets, and develops speciality plasma-derived biologics. It conducts operations through the following business segments: ADMA BioManufacturing and Plasma Collection Center.

[im-yf-promo]

While we acknowledge the potential of ADMA as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

[/im-yf-promo]

While we acknowledge the risk and potential of ADMA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ADMA and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.

Generated by RSStT. The copyright belongs to the original author.

Source